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Introduction: Intra-articular injection of corticosteroids (IIC) for treatment of patients with
juvenile idiopathic arthritis (JIA) is increasingly used in Pediatric Rheumatology.
Objectives: To describe the clinical course of patients undergoing IIC in our Pediatric Rheuma-
tology Unit.
Methods: Retrospective study of patients with JIA undergoing IIC from January 2008 to
December 2012, with a minimum follow-up of six months after the injection. Good response
to  IIC was set as the presence of inactivity on the inﬁltrated joint by at least six months.
Results: Eighty-eight patients underwent a total of 165 IICs. Of these, 75% were girls and
35.2%  had persistent oligoarticular JIA. The mean age at diagnosis was 6.8 years, and when
IIC  was carried out, 12.2 years. Regarding patients, younger age at diagnosis (p = 0.037) and
the  occurrence of uveitis in the course of the disease (p = 0.015) were associated with good
response to IIC. From 165 IICs, 63% had a good response and joints remained inactive for
a  median of 18.1 months. The type of joint injection (p = 0.001), lesser values stated in the
overall visual analog scale by the physician (p = 0.015) and by parents/patient (p = 0.01) have
been associated with a good response to IIC. Nine adverse events (5.4%) were observed.
Conclusion: In our study, more than half of the joints showed a good response to IIC. Younger
patients at diagnosis and uveitis during the course of the disease had good response to IIC.
Knees, wrists and elbows were the joints that best responded to IIC. IIC proved to be a safeprocedure.
©  2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Inﬁltrac¸ão  intra-articular  em  pacientes  com  artrite  idiopática  juvenil:
fatores  associados  à  boa  resposta
Palavras-chave:
Inﬁltrac¸ão intra-articular
Artrite idiopática juvenil
Hexacetonido de triancinolona
Tratamento e uveíte
r  e  s  u  m  o
Introduc¸ão: A inﬁltrac¸ão intra-articular de corticosteroides (IIC) para tratamento de pacientes
com  artrite idiopática juvenil (AIJ) é cada vez mais usada em reumatologia pediátrica.
Objetivos: Descrever a evoluc¸ão clínica dos pacientes submetidos à IIC em nosso setor de
reumatologia pediátrica.
Métodos: Estudo retrospectivo de pacientes com AIJ submetidos à IIC de janeiro/2008 a
dezembro/2012, com seguimento mínimo de seis meses após a inﬁltrac¸ão. Boa resposta
à  IIC foi deﬁnida como inatividade na articulac¸ão inﬁltrada por, no mínimo, seis meses.
Resultados: Foram submetidos a 88 pacientes a 165 IICs. Desses, 75% eram meninas e 35,2%
apresentavam AIJ oligoarticular persistente. A média de idade ao diagnóstico foi de 6,8 anos
e  à IIC de 12,2 anos. Em relac¸ão aos pacientes, a menor idade ao diagnóstico (p = 0,037) e a
ocorrência de uveíte no curso da doenc¸a (p = 0,015) foram associados à boa resposta à IIC.
Das  165 IICs, 63% apresentaram boa resposta e as articulac¸ões permaneceram inativas por
um  tempo médio de 18,1 meses. O tipo de articulac¸ão inﬁltrada (p = 0,001), menores valores
na  escala visual analógica global do médico (p = 0,015) e dos pais/paciente (p = 0,01) foram
associados a uma boa resposta à IIC. Nove efeitos adversos (5,4%) foram observados.
Conclusão: Em nosso estudo, mais da metade das articulac¸ões mostrou boa resposta à IIC.
Os  pacientes com menor idade ao diagnóstico e uveíte durante o curso da doenc¸a tiveram
boa resposta à IIC. Os joelhos, punhos e cotovelos foram as articulac¸ões que mais bem
responderam à IIC. A IIC mostrou ser um procedimento seguro.
©  2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma  licenc¸a CC
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introduction
uvenile idiopathic arthritis (JIA) is a chronic rheumatic dis-
ase most common in childhood, being a signiﬁcant cause of
isability and reduced quality of life.1
The goal of JIA treatment is to control inﬂamma-
ion and prevent a premature loss of cartilage and
oint function. JIA can be treated with a combination of
on-steroidal anti-inﬂammatory drugs (NSAIDs), disease-
odifying antirheumatic drugs (DMARDs), biologic drugs,
ystemic corticosteroids, intra-articular injections of cortico-
teroids (IIC) and physiotherapy.1–4
IIC is often used to treat JIA.5,6 Currently this procedure
s in use not only in patients with the oligoarticular subtype
i.e. those with a poor response to NSAIDs and as a ﬁrst-line
herapy), but also in those suffering a lengthy or complicated
rthritis (accompanied by joint contractures and growth dis-
rders), or even in those cases where one is awaiting by the
herapeutic effect of DMARDs.2,7–10
Although the long-term efﬁcacy and the potential effect
n activity and progression of JIA still need more  studies, IIC
an promote signiﬁcant pain relief, functional joint improve-
ent, and an increased likelihood of deformity correction and
f adaptation of bone growth. In addition, IIC is considered
s a safe and effective method to treat affected joints.1,11–16
urthermore, this procedure allows an early rehabilitation
nd a reduction – or even discontinuation – of systemic
edications.16,17
Most of our knowledge on joint injection comes from stud-
es in adults, with few reports in children. This study describesBY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
the clinical outcome of patients undergoing IIC in a Pediatric
Rheumatology Unit at UNIFESP over a period of ﬁve years, and
also evaluates factors associated with a good response to this
therapy.
Patients  and  methods
This is a retrospective study of medical records of patients
with JIA, who were followed at the Pediatric Rheumatology
unit of UNIFESP and submitted to IIC in the period from Jan-
uary 1, 2008 to December 31, 2012. Their inclusion criterion
was a minimum 6-month follow-up after the joint injection.
Patients with IICs procedures performed in other units were
excluded.
Demographic and clinical data of each patient were
assessed, and a preliminary classiﬁcation and evolution of
JIA was carried out according to the criteria of the Interna-
tional League of Associations for Rheumatology (ILAR)18: the
presence of uveitis in the course of disease, the presence of
autoantibodies (antinuclear antibody – ANA – considered as
positive for children with titles ≥1:160, and rheumatoid factor
– RF) and of human leukocyte antigen (HLA) B27.
For each intra-articular injection, we  assessed the dose
of medication used into each joint and the patient’s body
weight, a clinical classiﬁcation of the severity of joint effu-
sion (mild, moderate or severe) at the time of injection, and
whether the physician used ultrasound (US) to guide the injec-
tion. We also evaluated the patient’s age, number of active
and restricted joints, systemic medications used, the Child-
hood Health Assessment Questionnaire (CHAQ) score, a global
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visual analog scale (VAS, 0–10) value assigned by the physician
and by parents/patient, C-reactive protein (CRP), and erythro-
cyte sedimentation rate (ESR) at the time of injection. Adverse
events were recorded after each injection.
IICs were performed by a single pediatric rheumatologist
trained according to protocols speciﬁc for each type of joint.19
Injections were performed under local anesthesia with 2%
lidocaine without vasoconstrictor. The only medication used
was triamcinolone hexacetonide in doses of 1–2 mg/kg for
large joints, 0.5–1 mg/kg for medium joints, and 4–10 mg  for
small joints, with a maximum dose of 100 mg.  The patients
were asked to rest their joint after the procedure for a period
of 48 h.
We  considered a joint as inactive in the absence of arthritis
checked by clinical examination and/or US. The patient was
considered as with a good response to IIC when all injected
joints remained inactive for at least six months (complete
response) or when some of injected joints remained inactive
for at least six months (partial response). Poor response was
deﬁned as when all inﬁltrated joints remained active or exhib-
ited reactivation within a period under six months after IIC.
The answer to IIC in each joint was ranked as “good response”
(the inﬁltrated joint remained inactive for at least six months)
and “poor response” (the inﬁltrated joint did not answer, or its
reactivation occurred in less than six months).
Demographic and clinical characteristics were described
in absolute and relative frequencies, means ± standard devi-
ation, and minimum and maximum values, according to the
nature of the variables. To compare the distributions of con-
tinuous variables between two groups, Student’s t test or
Mann–Whitney test was used, taking into account the data
normality. Categorical variables between groups were com-
pared using the Chi-squared test or Fisher’s exact test. The
statistical signiﬁcance was set at 5%.
This study was approved by the Research Ethics Committee
of the Universidade Federal de São Paulo (Opinion Number:
326 891).
Results
From January 2008 to December 2012, 88 patients with JIA were
subjected to a total of 165 IICs, with a mean of 1.87 (range, 1–6)
injections per patient. The mean length of follow-up was 7.1
(0.8–17.1) years.
Sixty-two patients (70.4%) had a good response to IIC, 39
(44.3%) patients achieved a complete response, 23 (26.1%) were
beneﬁted with a partial response to IIC, and 26 patients (29.5%)
exhibited a poor response to all IICs to which they were sub-
jected. For the sake of our statistical analysis, subtypes of JIA
were grouped according to the course of the disease in: oligoar-
ticular – 37.5% (persistent oligoarticular JIA, enthesitis-related
arthritis [ERA], and psoriatic JIA [patients with a maximum of 4
affected joints]), polyarticular – 58% (polyarticular RF-positive
JIA, polyarticular RF-negative JIA, and extended oligoarticu-
lar JIA) and systemic – 4.5%. Regarding our evaluation per
patient, a good response to IIC was associated with younger
age at diagnosis of JIA (p = 0.037) and also for those patients
with uveitis occurring at any time in the course of the disease
(p = 0.015). Of 21 patients with uveitis, 13 were ANA positive. 0 1 6;5 6(6):490–496
Eleven patients were investigated for the presence of HLA-B27
and all of them were negative. Table 1 lists demographic and
clinical data for the group of patients.
Regarding the 165 joints injected, 104 (63%) showed good
response to IIC, which was associated with lower VAS values
assigned by the physician (p = 0.015) and by parents/patient
(p = 0.010). The lowest values of VAS were associated with a
better general condition of the patient with good response
to IIC, and with less pain and inﬂammatory activity. Further-
more, the type of joint submitted to injection (p = 0.001), also
was associated with a good response to IIC; knees, wrists,
and elbows were those joints showing better response to IIC.
Table 2 lists data relating to intra-articular injections.
Generally, US-guided injections in this small sample of 16
patients with longer disease duration and previous injections
showed poor response to IICs (p = 0.02); this fact is associated
with higher values of CHAQ (p = 0.03), higher number of injec-
tions with poor response (p = 0.01) and a shorter time to relapse
(p = 0.02) compared to patients submitted to blindly performed
procedures. Data related to US-guided injections are shown in
Table 3.
The joints that responded favorably to IIC remained inac-
tive for a mean of 18.1 ± 13.2 months. On the other hand, in
those joints with poor response, there was recurrence after a
mean period of 2.6 ± 2.1 months.
Of the 165 injections carried out, 43 (26.1%) were applied
in 17 patients whose joints were inﬁltrated in more  than one
occasion (14 knees, 3 ankles, and 2 hips), with a mean of 2.26
(range, 2–3) IICs per joint. Among these joints, 24 (55.8%) had a
good response to IIC, with a mean time of 12.3 months of joint
inactivity after the procedure.
Taking into account the total number of IICs performed,
nine (5.4%) adverse effects occurred in nine patients: ﬁve cases
of periarticular hypotrophy and four cases of hypochromia at
the site of injection.
Discussion
In this study, we observed a good response to IIC in more  than
half of patients, especially those younger-aged at the diagno-
sis of JIA, and patients presenting uveitis during the course
of the disease. Additionally, the type of injected joint (knees,
wrists, and elbows) and low values of VAS assigned by the
physician and by the parents/patient were associated with a
good response to IIC. The use of US to guide the procedures
was  associated with worse responses to IIC.
Of the total number of IICs performed out, more  than half
presented inactivity of arthritis for more  than 6 months, with
a mean duration of about one and a half years. The inactivity
rates after the injection varies depending on the study: around
56.1–82% after six months, 42–80% after 1 year, and 30–63%
after 2 years.5,10,12–14,20–22 The literature reveals a wide varia-
tion among studies with respect to mean response duration
time in patients with JIA, ranging from 6 to 23.5 months.7,23–25
Among the potential factors associated with a good
response to IIC described in the literature, we  found absence
of ANA,11,23 presence of HLA-B27,23 absence of atrophy in the
local of injection,23 concomitant use of MTX,7,10,23 oligoartic-
ular subtype of JIA,7,10,20 and use of sedation.23 In this study,
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Table 1 – Demographic and clinical data of patients who underwent joint injections.
Variables Total of
patients
(n = 88)
Good
response to
IIC (n = 62)
Poor response
to IIC (n = 26)
p-Value
Demographic data
Female gender 66 48 (72.7%) 18 (27.3%) 0.42a
Time elapsed between the ﬁrst
symptoms and diagnosis (months)
10.5  (±16.5) 11.7 (±18.9) 7.8 (±7.8) 0.73b
Age at diagnosis of JIA (years) 6.8 (±4.0) 6.2 (±3.7) 8.3 (±4.4) 0.037b
Mean follow-up to the last visit (years) 7.1 (±4.0) 7.5 (±3.9) 6.1 (4.1) 0.08b
ANA, positive 37 30 (81%) 7 (19%) 0.126a
RF, positive 9  8 (88.9%) 1 (11.1%) 0.271c
Uveitis associated with JIA 12  12 (100%) 0 0.015c
JIA subtype 0.076a
Systemic 4 1 (25%) 3 (75%)
Oligoarticular, persistent 31 22 (70.9%) 9 (29.1%)
Oligoarticular, extended 17 14 (82.3%) 3 (17.7%)
Polyarticular, RF positive 9 8 (88.9%) 1 (11.1%)
Polyarticular, RF negative 25 17 (68%) 8 (32%)
Psoriatic 1 0 1 (100%)
ARE 1 0 1 (100%)
Clustered subtype of JIA 0.08a
Oligoarticular 33 22 (66.7%) 11 (33.3%)
Polyarticular 51 39 (76.4%) 12 (23.6%)
Systemic 4 1 (25%) 3 (75%)
IIC, intra-articular injection of corticosteroids; ANA, antinuclear antibody; RF, rheumatoid factor; JIA, juvenile idiopathic arthritis; ARE, arthritis
related to enthesitis.
a Chi-squared test.
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resence of ANA, use of DMARDs, and JIA subtype were not
ssociated with a better or worse response to IIC. Among our
atients, none was HLA B-27-positive and in none of them IIC
as performed under sedation, which prevented the assess-
ent of these factors.
The literature also describes as indicators of worse
esponse: absence of ANA (contrary to the studies cited
bove),7,10 increases in CRP and ESR,7,10,22 systemic and pol-
articular JIA subtypes,7,10,20,25 and elbow inﬁltration.10 In our
tudy we  found a good response to elbow injection. Despite the
mall number of patients with systemic JIA in this study, and
aking into account that no statistical signiﬁcance was found,
e also noted worse responses to IIC in patients with systemic
IA, showing that the procedure in this disease subtype should
e evaluated individually.
No association was observed between the occurrence
f uveitis and a better response to IIC in the study con-
ucted by Marti et al.,23 contrary to our study, where the
ccurrence of uveitis was associated with a better response
o IIC.
Compared to VAS values assigned by the physician and by
arents/patient, these parameters were not associated with
esponse to IIC in the study by Ravelli et al.22 On the other
and, the study by Moretti et al.26 showed that a lower VAS
alue assigned by the physician was a good predictor of
esponse to IIC in patients with the oligoarticular subtype. In
ur study, higher procedure values of VAS, both assigned by
he physician and the patient, were associated with a worse
esponse to IIC.Studies suggest that the best time for the completion of
an IIC procedure is as early as possible in the course of the
disease – and this is a factor of good response to IIC.11,16 In
our study, we  found that younger-aged patients at diagnosis
showed a good response to IIC. This may be related to the most
common subtype in this age group, which is the oligoarticular
subtype; but also demonstrates that, by being younger, these
patients could be in an earlier stage of the disease, which is in
line with literature ﬁndings.
One may obtain a long-lasting answer to IIC when
using hexacetonide triamcinolone versus acetonide
triamcinolone.5,21,23,27,28 Thus, we chose to use hexacetonide
triamcinolone in all of our injections.
There is evidence in favor of a better response to IIC when
the procedure is guided by an imaging technology (ultrasound
or MRI), especially in the wrist, ankle and hip.3,29,30 Contrary
to this, we found a poor response to US-guided IIC injection.
This ﬁnding may be due to the fact that, in our study, guided
injections were performed on joints that had already showed
a poor response to blindly-conducted IIC, and is likely that this
played a role in our results. Prospective studies in joints never
subjected to injection should be conducted, in order to better
assess the utility of US to guide IIC in children.
The completion of multiple injections into the same joint
proved to be a successful alternative therapy, taking into
account that in our study, more  than half of patients under-
going this procedure have been beneﬁted. In our routine, we
wait for at least 1 month to repeat the inﬁltration in the same
joint.
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Table 2 – Demographic and clinical data related to joints subjected to injection.
Variables Total of patients
(n = 165)
Good  response to
IIC (n = 104)
Poor response to
IIC (n = 61)
p-Value
Descriptor
Time from diagnosis to IIC (years) 5.3 (±3.8) 5.6 (±3.8) 4.9 (±3.8) 0.25a
Age at IIC (years) 12.2 (±4.3) 12.1 (±4.5) 12.5 (±4.1) 0.53a
CHAQ (n = 28), mean (range) 0.41 (0–2.25) 0.30 (0–2.25) 0. 67 (0–1.75) 0.53a
VAS parents/patient (n = 80), median (range) 0 (0–9) 0 (0–9) 3 (0–8) 0.015a
VAS physician (n = 60), median (range) 1 (0–8) 0 (0–7) 4 (1–8) 0.010a
CRP (n = 124) ± SD 10.2 (±18.5) 10.5 (±21.6) 9.6 (±11.9) 0.22a
ESR (n = 129) ± SD 25.8 (±24.5) 27.2 (±26.7) 23.2 (±20.3) 0.41a
Active joints ± SD 3.1  (±4.3) 2.6 (±3.0) 4.1 (±5.8) 0.09a
Restricted joints ± SD 3.2  (±6.1) 3.0 (±5.6) 3.5 (±6.9) 0.77a
Injected joint 0.001b
Knees 100 71 (71%) 29 (29%)
Ankles 30 11 (36.7%) 19 (63.3%)
Wrists 15 10 (66.7%) 5 (33.3%)
Elbows 9 9 (100%) 0
Shoulders 3 1 (33.3%) 2 (66.7%)
Hips 6 2 (33.3%) 4 (66.7%)
Proximal interphalangeal joints 2 0 2 (100%)
Joint effusion degree (n = 156) 0.49b
Mild 55 33 (60%) 22 (40%)
Moderate 84 56 (66.7%) 28 (33.3%)
Severe 17 9 (52.9%) 8 (47.1%)
Guided by ultrasound 16  6 (37.5%) 10 (62.5%) 0.02b
Drugs in use at the time of IIC 0.32b
None or NSAIDs 55 39 (71%) 16 (29%)
DMARDs 80 48 (60%) 32 (40%)
Biologicals 30 17 (56.7%) 13 (43.3%)
Use of oral corticosteroids 21 12 (57.1%) 9 (42.9%) 0.55b
IIC, intra-articular injection corticosteroids; SD, standard deviation; CHAQ, Childhood Health Assessment Questionnaire; VAS, visual analog
scale; CRP, C-reactive protein, ESR, erythrocyte sedimentation rate; NSAIDs, nonsteroidal anti-inﬂammatory drugs; DMARDs, disease-modifying
antirheumatic drugs.
a Mann–Whitney test.
b Chi-squared test.
Table 3 – Comparison between injection guided versus not guided by ultrasound (US).
Variables US-guided inﬁltrations
(n = 16)
Inﬁltrations unguided by US
(n = 149)
p-Value
Descriptor
Time from diagnosis to IIC (years) 5.9 (±3.4) 5.2 (±3.7) 0.63a
Age at IIC (years) 12.1 (±5.2) 12.2 (±4.2) 0.94a
CHAQ (n = 28), mean (range) 1.6 (1–2.25) 0.3 (0–1.75) 0.03a
VAS parents/patient (n = 80), median (range) 5 (1–6) 0 (0–9) 0.42a
VAS physician (n = 60), median (range) 1 (1–4) 3 (0–8) 0.46a
CRP (n = 124) ± SD 11 (±17.5) 10 (±18.6) 0.89a
ESR (n = 129) ± SD 25.3 (±18.4) 25.8 (±25.2) 0.73a
Active joints ± SD 4.5 (±6.7) 2.9 (±3.9) 0.55a
Restricted joints ± SD 6.7 (±12.8) 2.8 (±4.8) 0.30a
Number of injections with poor response 1.4 (±0.8) 0.8 (±0.8) 0.01a
Relapse time (months) 6.5 (±7.2) 13 (±13.2) 0.01a
Joint effusion degree (n = 156) 0.29b
Mild 7 48
Moderate 8 76
Severe 0 17
IIC, intra-articular injection of corticosteroids; SD, standard deviation; CHAQ, Childhood Health Assessment Questionnaire; VAS, visual analog
scale; CRP, C-reactive protein, ESR, erythrocyte sedimentation rate.
a Mann–Whitney test.
b Chi-squared test.
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The most common adverse events are: local subcuta-
eous tissue atrophy at the IIC site,5,7,10,21–23,25,29 local skin
ypopigmentation,25,29 acute onset of pain (joint irritation by
rystals of the drug),27 local calciﬁcation,25 adverse effects
elated to general/local anesthesia,23 and possible systemic
ffects of corticosteroids (facial ﬂushing, increased appetite,
ood swings).23,25,29 Post-injection infection is a rare event in
dults,27 and there are no published reports of pediatric cases.
n our study, we  observed a low rate of adverse events, none
f which was characterized as a severe event.
Our study showed that IIC is an effective and sustained
herapeutic modality; more  than half of our patients presented
 good response to the procedure. Furthermore, ICC is a safe
ethod with a low rate of adverse events. To the best of our
nowledge, this is the ﬁrst study in children and adolescents
ith JIA in our population, that sought to assess the factors
ssociated with IIC response. However, this study has some
imitations, such as its retrospective design, which affected
ata collection. And we  also did not include data from injec-
ions applied to these patients in other units, which occurred
n a few cases. More  prospective studies are needed to better
eﬁne the proﬁle of patients with JIA who may beneﬁt from
IC procedures.
Our study also showed that a younger age at the diagnosis
f JIA, occurrence of uveitis in the course of the disease, as well
s knee, wrist and elbow injection and lower VAS values both
rom the physician and patient were factors associated with a
etter response to IIC. IIC is an effective therapeutic modality
resenting a sustained response. Furthermore, it is also a safe
rocedure that can contribute to improving the quality of life
f patients with JIA.
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